Neuphoria Therapeutics (NEUP) Operating Leases (2020 - 2025)

Neuphoria Therapeutics (NEUP) has reported Operating Leases for 6 consecutive years, with $19322.0 the latest figure, recorded in Q1 2025.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $19322.0 in Q1 2025; TTM through Mar 2025 was $19322.0, a N/A change from a year earlier, with the FY2024 full-year figure at $117628.0, down 50.95% from the prior year.
• Operating Leases was $19322.0 for Q1 2025 at Neuphoria Therapeutics, down from $49818.0 in the prior quarter.
• Over five years, Operating Leases peaked at $534128.0 in Q2 2021 and troughed at $19322.0 in Q1 2025.
• A 5-year average of $204903.9 and a median of $117628.0 in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases soared 3103.76% in 2021 and slumped 51.35% in 2024, its largest moves.
• Over 5 years, Operating Leases stood at $534128.0 in 2021, then slipped by 28.45% to $382188.6 in 2022, then plunged by 36.74% to $241774.0 in 2023, then slumped by 79.39% to $49818.0 in 2024, then tumbled by 61.21% to $19322.0 in 2025.
• The last three Operating Leases figures came in at $19322.0 (Q1 2025), $49818.0 (Q4 2024), and $89469.0 (Q3 2024), per Business Quant data.